SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Leighl, NB; Redman, MW; Rizvi, NA; Hirsch, FR; Mack, PC; Schwartz, LH; Wade, JL; Irvin, WJ; Reddy, S; Crawford, J; Bradley, JD; Stinchcombe, T; Ramalingam, SS; Miao, J; Minichiello, K; Gandara, DR; Herbst, RS; Papadimitrakopoulou, V; Kelly, K

Published Date

  • May 20, 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X